Home > Oncology > ASCO GI 2022 > Anal and Colorectal Cancer > Analysis of metastasectomy in CRC reveals benefits and disparities

Analysis of metastasectomy in CRC reveals benefits and disparities

Presented By
Dr Jude Khatib (University of Texas, TX, USA
Conference
ASCO GI 2022
Metastasectomy is associated with improved overall survival in patients with colorectal cancer (CRC) and concurrent lung and liver metastasis. However, this approach is not often utilised, as a study of the National Cancer Database showed. The authors concluded that future studies are needed to improve the identification of patients who may benefit from metastasectomy [1]. Dr Jude Khatib (University of Texas, TX, USA) explained that CRC is associated with concurrent lung and liver metastasis. The current study aimed to assess the trends in the utilisation of metastasectomy in patients with CRC and concurrent lung and liver metastasis, and the effect of this treatment option on survival. Patients with stage 4 CRC who displayed concurrent liver and lung metastasis between 2010 and 2016 were selected from the National Cancer Database (n=10,106). Only 6.2% of this population underwent metastasectomy, whereas 93.8% did not. The patients that underwent me...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on